Radonuclide Therapy:Radium2

[M2B2C1] Interim analysis results from a post-marketing surveillance of Ra-223 in mCRPC patients

Seigo Kinuya¹, Yoshiyuki Kakehi², Naoya Masumori³, Shunji Takahashi⁴, Makoto Hosono⁵, Kazufumi Hirano⁶, Yasuhiro Matsuba⁶, Toshiyuki Sunaya⁷, Hirotsugu Uemura⁸ (1.Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan, 2.Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan, 3.Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan, 4.Department of Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan, 5.Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, 6.Pharmacovigilance, Medical Affairs, Bayer Yakuhin, Ltd, Osaka, Japan, 7.Clinical Statistics, Product Development, Bayer Yakuhin, Ltd, Osaka, Japan, 8.Department of Urology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan)